Suspension ir (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00782600 (ClinicalTrials.gov) | July 2008 | 27/10/2008 | Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers | A Phase 1, Randomized, 4-Period, 4-Sequence Cross-Over Study Of The Pharmacokinetics Of 3 Durations Of Release Of A Controlled Release Formulation And A Single Dose Of An Immediate Release Oral Suspension Of CE-224,535 In Normal Healthy Volunteers | Rheumatoid Arthritis | Drug: suspension IR;Drug: CR 1;Drug: CR 2;Drug: CR 3 | Pfizer | NULL | Completed | 18 Years | 55 Years | Both | 16 | Phase 1 | United States |